Free Trial

Organovo (ONVO) Competitors

$1.00
+0.01 (+0.65%)
(As of 05/24/2024 04:00 PM ET)

ONVO vs. MBOT, AIM, OKYO, BCLI, ACHL, QNCX, ESLA, NKGN, SRZN, and INKT

Should you be buying Organovo stock or one of its competitors? The main competitors of Organovo include Microbot Medical (MBOT), AIM ImmunoTech (AIM), OKYO Pharma (OKYO), Brainstorm Cell Therapeutics (BCLI), Achilles Therapeutics (ACHL), Quince Therapeutics (QNCX), Estrella Immunopharma (ESLA), NKGen Biotech (NKGN), Surrozen (SRZN), and MiNK Therapeutics (INKT). These companies are all part of the "medical" sector.

Organovo vs.

Organovo (NASDAQ:ONVO) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

8.2% of Organovo shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 5.0% of Organovo shares are owned by insiders. Comparatively, 10.6% of Microbot Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Microbot Medical has lower revenue, but higher earnings than Organovo. Microbot Medical is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organovo$370K27.06-$17.26M-$2.17-0.46
Microbot MedicalN/AN/A-$10.74M-$0.89-1.15

Microbot Medical received 150 more outperform votes than Organovo when rated by MarketBeat users. Likewise, 70.61% of users gave Microbot Medical an outperform vote while only 50.26% of users gave Organovo an outperform vote.

CompanyUnderperformOutperform
OrganovoOutperform Votes
196
50.26%
Underperform Votes
194
49.74%
Microbot MedicalOutperform Votes
346
70.61%
Underperform Votes
144
29.39%

In the previous week, Organovo had 1 more articles in the media than Microbot Medical. MarketBeat recorded 3 mentions for Organovo and 2 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 1.89 beat Organovo's score of 0.62 indicating that Microbot Medical is being referred to more favorably in the news media.

Company Overall Sentiment
Organovo Positive
Microbot Medical Very Positive

Organovo has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500.

Microbot Medical has a consensus target price of $7.00, suggesting a potential upside of 586.27%. Given Microbot Medical's higher probable upside, analysts clearly believe Microbot Medical is more favorable than Organovo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organovo
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Microbot Medical
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Microbot Medical's return on equity of -149.24% beat Organovo's return on equity.

Company Net Margins Return on Equity Return on Assets
OrganovoN/A -182.88% -138.52%
Microbot Medical N/A -149.24%-115.69%

Summary

Microbot Medical beats Organovo on 12 of the 15 factors compared between the two stocks.

Get Organovo News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONVO vs. The Competition

MetricOrganovoBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$10.01M$2.91B$4.97B$8.03B
Dividend YieldN/A2.24%5.30%3.96%
P/E Ratio-0.4616.51134.9316.65
Price / Sales27.06357.442,574.9474.07
Price / CashN/A162.8532.7428.77
Price / Book0.574.114.964.42
Net Income-$17.26M-$45.70M$103.46M$213.06M
7 Day Performance-7.65%-3.12%-1.25%-0.51%
1 Month Performance-0.26%5.61%3.44%3.92%
1 Year Performance-48.05%3.59%5.48%7.89%

Organovo Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBOT
Microbot Medical
1.8009 of 5 stars
$1.02
-2.9%
$7.00
+586.3%
-51.7%$14.69MN/A-1.1521
AIM
AIM ImmunoTech
0 of 5 stars
$0.39
-2.5%
N/A-19.5%$19.74M$200,000.00-0.6026Negative News
Gap Up
OKYO
OKYO Pharma
3.0813 of 5 stars
$1.32
-10.8%
$7.00
+430.3%
-3.6%$38.06MN/A0.008Positive News
Gap Down
BCLI
Brainstorm Cell Therapeutics
0.8946 of 5 stars
$0.54
-6.9%
N/A-81.7%$37.65MN/A-1.6829Analyst Forecast
ACHL
Achilles Therapeutics
2.5178 of 5 stars
$0.91
+1.1%
$4.00
+339.6%
-10.0%$37.39MN/A-0.57204Positive News
QNCX
Quince Therapeutics
0 of 5 stars
$0.85
-2.3%
N/A-41.8%$36.73MN/A-1.1232Positive News
ESLA
Estrella Immunopharma
0 of 5 stars
$0.99
-1.0%
N/AN/A$36.09MN/A0.00N/AHigh Trading Volume
NKGN
NKGen Biotech
0 of 5 stars
$1.42
-23.7%
N/AN/A$35.34M$80,000.000.00N/AEarnings Report
SRZN
Surrozen
2.5418 of 5 stars
$10.45
+1.6%
N/A+7.5%$33.44M$12.50M0.0042Positive News
Gap Down
INKT
MiNK Therapeutics
1.7807 of 5 stars
$0.96
-2.0%
$9.00
+837.5%
-50.0%$33.34MN/A-1.6031

Related Companies and Tools

This page (NASDAQ:ONVO) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners